Does Rhode Island Medicaid cover Wegovy and Zepbound in 2026?
No, not since Oct 1, 2026. As of Oct 23, 2026, Rhode Island Medicaid no longer covers GLP-1 drugs for obesity alone.
Coverage ended in 2026 Checked Oct 23, 2026 Coverage ended Oct 1, 2026
Coverage of GLP-1 drugs for obesity alone under Rhode Island’s fee-for-service Medicaid drug rules, as the state publishes them. The plan decides each request.
Rhode Island’s rule
In plain words
Coverage ended in 2026
No longer covered when prescribed solely for weight loss, from Oct 1, 2026 (state budget).
Source
RI EOHHS provider memo, Aug 5, 2026 (opens in new tab). Checked Oct 23, 2026.
Federal Medicaid law lets a state exclude these drugs only “when used for anorexia, weight loss, or weight gain”; their use for type 2 diabetes is not on that list, though a state may require prior authorization. Social Security Act §1927(d)(1)(A) and (d)(2)(A), 42 U.S.C. 1396r-8(d) (opens in new tab).
What changed
- Oct 1, 2026: Rhode Island Medicaid stopped covering Foundayo, Saxenda, Wegovy and Zepbound when prescribed solely for weight loss. RI EOHHS provider memo, Aug 5, 2026 (opens in new tab)
Questions this page answers
Does Rhode Island Medicaid cover Wegovy and Zepbound for weight loss?
No, not since Oct 1, 2026. As of Oct 23, 2026, Rhode Island Medicaid no longer covers GLP-1 drugs for obesity alone. No longer covered when prescribed solely for weight loss, from Oct 1, 2026 (state budget).
Has Rhode Island’s rule changed recently?
Oct 1, 2026: Rhode Island Medicaid stopped covering Foundayo, Saxenda, Wegovy and Zepbound when prescribed solely for weight loss.
Where does this information come from?
From RI EOHHS provider memo, Aug 5, 2026, read on Oct 23, 2026. Federal Medicaid law lets a state exclude these drugs only “when used for anorexia, weight loss, or weight gain”; their use for type 2 diabetes is not on that list, though a state may require prior authorization.
Kymata Health reads each state’s own Medicaid documents. See every state on the map.